Biogen Acquires Apellis for $5.6B, Expanding Beyond Neuro into Immunology

Biogen's tender offer for Apellis Pharmaceuticals adds Empaveli and Syfovre (combined ~$689M 2025 revenue) and a nephrology pipeline, diversifying beyond its slowing MS franchise. The deal signals complement-pathway biology is now worth blockbuster acquisition prices.